New drug tested to quiet debilitating cough in serious lung disease
NCT ID NCT05185089
Summary
This study tested whether a drug called orvepitant could reduce the severity and frequency of chronic cough in people with idiopathic pulmonary fibrosis (IPF), a serious scarring lung disease. In this completed Phase 2 trial, 80 participants tried both the study drug and a placebo in a random order to see which worked better. The main goal was to see if orvepitant could make patients' daily cough less severe and improve their quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Altnagelvin Area Hospital
Londonderry, Northern Ireland, BT47 6SB, United Kingdom
-
American Health Research
Charlotte, North Carolina, 28277, United States
-
Antrim Area Hospital
Antrim, Northern Ireland, BT41 2RL, United Kingdom
-
Baylor University
Dallas, Texas, 75246, United States
-
Castle Hill Hospital
Cottingham, Hull, HU16 5JQ, United Kingdom
-
Churchill Hospital
Headington, Oxford, OX3 7LE, United Kingdom
-
Clear Lake Health
Webster, Texas, 77598, United States
-
Erasmus University Medical Centre
Rotterdam, 3015 GD, Netherlands
-
Guy's Hospital
London, SE1 9RT, United Kingdom
-
Heartlands Hospital
Birmingham, B9 5SS, United Kingdom
-
Isala Ziekenhuis
Zwolle, 8025 AB, Netherlands
-
Jadestone Clinical Research, LLC
Silver Spring, Maryland, 20904, United States
-
Loyola University Chicago
Maywood, Illinois, 60153, United States
-
MAC Clinical Research
Prescot, Merseyside, L34 1BH, United Kingdom
-
MAC Clinical Research
Barnsley, South Yorkshire, S75 3DL, United Kingdom
-
MAC Clinical Research
Leeds, West Yorkshire, LS10 1DU, United Kingdom
-
MAC Clinical Research
Manchester, M13 9NQ, United Kingdom
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29424, United States
-
National Jewish Health
Denver, Colorado, 80206, United States
-
Nottingham City Hospital
Nottingham, NG5 1PB, United Kingdom
-
Perth Royal Infirmary
Perth, Perth and Kinross, PH1 1NX, United Kingdom
-
PulmonIx, LLC
Greensboro, North Carolina, 27403, United States
-
Royal Berkshire Hospital
Reading, Berkshire, RG1 5AN, United Kingdom
-
Royal Devon and Exeter Hospital
Exeter, EX2 5DW, United Kingdom
-
Royal Infirmary of Edinburgh
Edinburgh, Scotland, EH16 4SA, United Kingdom
-
Royal Papworth Hospital
Cambridge, CB2 0AY, United Kingdom
-
Sint Antonius Hospital
Nieuwegein, 3435 CM, Netherlands
-
Southampton General Hospital
Southampton, SO16 6YD, United Kingdom
-
Temple University
Philadelphia, Pennsylvania, 19140, United States
-
University of California
San Francisco, California, 94143, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Southern California
Los Angeles, California, 90033, United States
-
University of Utah
Salt Lake City, Utah, 84108, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37204, United States
-
Zuyderland Medical Centre
Heerlen, 6419 PC, Netherlands
Conditions
Explore the condition pages connected to this study.